MedTrace Logo

Phase II Proof-of-concept Study of APD421

NCT01303978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2012-09-25

No results posted yet for this study

Summary

Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

APD421

Single dose

Sponsors & Collaborators

  • Acacia Pharma Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01303978 on ClinicalTrials.gov